Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

GPs discriminated against on medical education pay

From Dr Dinesh Kapoor

CHD Lead, Waltham Forest PCT

The ASCOT trial (News, 10 September) is welcome news for the silently suffering hypertensive patients on ß-blockers who have been too embarrassed to complain about their erectile dysfunction side-effects.

For months now I have been practising and preaching the use of an ACE inhibitor or a calcium channel blocker in place of ß-blockers in hypertension and I am therefore for the ASCOT findings.

Let the Department of Health pick up the cost issue as saving cost would not be a good advert for the Government in this case.

Benefits of an ACE inhibitor are well-established in diabetes and CHD and let this class of drugs (or a sartan in case of intolerance) be the mainstream treatment for hypertension.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say